CO95 Matching-Adjusted Indirect Comparison (MAIC) in Previously Treated KRAS G12C-Mutated Advanced/Metastatic Non-Small Cell Lung Cancer (a/mNSCLC): Adagrasib Versus Sotorasib

A new class of therapies targeting KRAS G12C has emerged in a/mNSCLC, with FDA approvals of sotorasib (May-2021) and adagrasib (December-2022). Adagrasib was investigated in KRYSTAL-1, a Phase 2, single-arm trial in a/mNSCLC patients pre-treated with chemoimmunotherapy. A MAIC evaluated efficacy and safety of adagrasib in KRYSTAL-1 versus sotorasib in CodeBreaK100, a Phase 2 single-arm trial in a/mNSCLC patients pretreated with chemotherapy and/or immunotherapy, and CodeBreaK200, a Phase 3 randomized controlled trial (RCT) in a/mNSCLC patients pretreated with chemoimmunotherapy.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research